From January to August of this year, the overall biomedical industry in Shanghai showed a high-quality development trend of “steady growth, strong innovation, excellent structure, and high vitality”. Yesterday, the reporter learned from the 2026 Zhangjiang Pharmaceutical Valley Conference and Shanghai International Biomedical Industry Week that Shanghai has achieved national leadership in the three core indicators of the number of high-end innovative devices approved, the scale of industrial financing, and the number of biomedical BD transactions. In terms of the output value of the biomedical manufacturing industry, from January to August, Shanghai achieved a cumulative output value of 138.165 billion yuan, a comparable increase of 8.2%. The industrial structure continues to be optimized, and the output value of innovative pharmaceutical companies accounted for 24.3%, a sharp jump from 8.1% at the end of the 13th Five-Year Plan and 20.9% at the end of the “14th Five-Year Plan”. The output value of innovative pharmaceutical companies can increase by 32.0%, which is 23.8 percentage points higher than the average growth rate of the city's industry. It directly drives the city's biomedical output value to increase by 6.5 percentage points, and has become the core engine of industrial growth. Among them, innovative devices had a comparable increase of 37.7%, and innovative drugs had a comparable increase of 26.6%.

From January to August of this year, the overall biomedical industry in Shanghai showed a high-quality development trend of “steady growth, strong innovation, excellent structure, and high vitality”. Yesterday, the reporter learned from the 2026 Zhangjiang Pharmaceutical Valley Conference and Shanghai International Biomedical Industry Week that Shanghai has achieved national leadership in the three core indicators of the number of high-end innovative devices approved, the scale of industrial financing, and the number of biomedical BD transactions. In terms of the output value of the biomedical manufacturing industry, from January to August, Shanghai achieved a cumulative output value of 138.165 billion yuan, a comparable increase of 8.2%. The industrial structure continues to be optimized, and the output value of innovative pharmaceutical companies accounted for 24.3%, a sharp jump from 8.1% at the end of the 13th Five-Year Plan and 20.9% at the end of the “14th Five-Year Plan”. The output value of innovative pharmaceutical companies can increase by 32.0%, which is 23.8 percentage points higher than the average growth rate of the city's industry. It directly drives the city's biomedical output value to increase by 6.5 percentage points, and has become the core engine of industrial growth. Among them, innovative devices had a comparable increase of 37.7%, and innovative drugs had a comparable increase of 26.6%.